Rxivist logo

SLAMF6 deficiency augments tumor killing and skews towards an effector phenotype revealing it as a new T cell checkpoint

By Emma Hajaj, Galit Eisenberg, Shiri Klein, Shoshana Frankenburg, Sharon Merims, Inna Ben-David, Thomas Eisenhaure, Sarah E. Henrickson, Alexandra-Chloe Villani, Nir Hacohen, Nathalie Abudi, Rinat Abramovich, Jonathan Cohen, Tamar Peretz, André Veillette, Michal Lotem

Posted 31 Oct 2019
bioRxiv DOI: 10.1101/824946 (published DOI: 10.7554/eLife.52539)

SLAMF6 is a homotypic receptor of the Ig-superfamily whose exact role in immune modulation has remained elusive. Its constitutive expression on resting and activated T cells precludes it from being a bona fide exhaustion marker. By breeding Pmel-1 mice with SLAMF6 KO mice, we generated donors for T cells lacking SLAMF6 and expressing a transgenic TCR for gp100-melanoma antigen. Activated Pmel-1xSLAMF6 KO CD8 T cells displayed improved polyfunctionality and strong tumor cytolysis. T-bet was the dominant transcription factor in Pmel-1xSLAMF6 KO cells, and upon activation, they acquired an effector-memory phenotype. Blocking LAG-3 improved the function of SLAMF6 deficient T cells even further. Finally, adoptive transfer of Pmel-1xSLAMF6 KO T cells into melanoma-bearing mice resulted in lasting tumor regression in contrast to temporary responses achieved with Pmel-1 T cells. These results support the notion that SLAMF6 is an inhibitory immune receptor whose absence enables powerful CD8 T cells to eradicate tumors.

Download data

  • Downloaded 312 times
  • Download rankings, all-time:
    • Site-wide: 82,736
    • In physiology: 683
  • Year to date:
    • Site-wide: 92,893
  • Since beginning of last month:
    • Site-wide: 94,658

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)